|Bid||92.00 x 900|
|Ask||94.47 x 800|
|Day's Range||92.72 - 94.60|
|52 Week Range||76.41 - 100.15|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||40.41|
|Earnings Date||Nov 20, 2018|
|Forward Dividend & Yield||2.00 (2.12%)|
|1y Target Est||104.00|
The "Mad Money" host will be watching for include key housing data, as well as news on interest rates and a potential trade deal. CNBC's Jim Cramer will be seeking out "man-made" buying opportunities for investors in the short week before Thanksgiving Day. "Immediately, there were questions about ... the validity or the sincerity of both of these statements," Cramer noted, referencing his own concern about the Fed's lack of rigor in its policymaking.
November 16, 2018 - Medtronic plc (MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those with hostile aortic neck anatomies. The new data were unveiled in presentations at the 45th Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium) in New York. The findings are based on three-year data from the primary prophylactic and therapeutic revision arms of the Medtronic ANCHOR registry - a global, multi-center, multi-arm, post-market registry evaluating the real-world applicability of the Heli-FX EndoAnchor System.
Medtronic (MDT) is expected to maintain a decent market share in the core pacing banking, backed by the continued rollout of Micra Transcatheter Pacing System.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced ...
November 9, 2018 - Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. The news release will include summary financial information for the company`s second quarter of fiscal year 2019, which ended on Friday, October 26, 2018. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2019.
2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, ...
November 8, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications. The SPYRAL HTN-ON MED Trial is the latest prospectively powered, randomized, sham-controlled study within the broader Medtronic SPYRAL HTN Global Clinical Program, and will evaluate a patient population comparable to what physicians typically encounter in daily practice - patients with uncontrolled blood pressure taking multiple anti-hypertensive medications.
November 6, 2018 - Medtronic plc (MDT) data presented today reinforce the durability, safety, and effectiveness of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the Total IN.PACT Pooled Analysis were presented in two late-breaking clinical trial presentations at the Vascular Interventional Advances (VIVA) 2018 conference in Las Vegas. "Since the entrance of DCBs into the market several years ago, we have seen a shift towards the use of this technology as a frontline therapy to treat patients with PAD," said Mark Pacyna, vice president and general manager of the Peripheral business in the Medtronic Cardiac & Vascular Group.
Type 1 diabetes is a disease that affects more than 1.2 million Americans. It's a disease that impairs the body's ability to produce the hormone insulin, which normally comes from the pancreas. Managing blood sugars can be very difficult, and patients use a pump to help mimic the activity of the pancreas.
Repligen is the IBD Stock Of The Day after the bioprocessor broke out for the second time this year on its 15th straight quarter of double-digit sales growth. Shares rose.
Wall Street analysts expect Sanofi’s (SNY) third-quarter revenues to increase 3.3% to 9.3 billion euros. Sanofi’s stock price has decreased nearly 11.0% over the last 12 months. The stock price has decreased ~1.7% in 2018 year-to-date.
A look at the shareholders of Medtronic plc (NYSE:MDT) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to Read More...
Following the September index review, the U.S. Moat Index remained overweight health care stocks. Rather than being an indication of Morningstar’s view of the sector as a whole, this reflects wide moat opportunities within the health care sector. The health care sector as a whole, as represented by the Morningstar US Healthcare Index, has fluctuated above and below fair value over the last five years, ending the period above fair value.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
America’s affluent generation of millennial socialists don’t realize it, but they are living off the prosperity created by earlier generations of capitalists. One of them was Earl E. Bakken, who died last week at age 94 having invented the first wearable, battery-powered pacemaker. Earl Bakken’s business life is an American classic.